



ABN 11 124 426 339
Level 3, 2-4 Ross Place, South Melbourne, VIC 3205
P +61 (3) 9673 9690 F +61 (3) 9673 9699
www.purifloh.com E corporate@purifloh.com

12 May 2021

ASX Announcements
4th Floor
20 Bridge Street
Sydney, NSW, 2000

Purifloh partners with Aspen Medical for supply of disinfection technologies

Purifloh Limited (ASX: PO3 "Purifloh" or "the Company") is pleased to announce it has entered into a partnership, by way of a Heads of Agreement, with Aspen Medical (<https://www.aspenmedical.com/>). The Agreement is non-binding, other than certain confidentiality clauses, but serves as a Statement of the Party's Intentions to enter into a partnership and subsequently a formal commercial agreement.

Executive Chairman and Founder of Aspen Medical, Glenn Keys AO, said *"We are very pleased to be partnering with Purifloh. The FRG technology is a powerful addition to our general infection control regimes for high-traffic enclosed spaces."*

Purifloh will supply its products to Aspen Medical for in the field deployment. The agreement signals the mutual intent to enter into a fuller and formal commercial agreement for exclusive supply and distribution within Aspen Medical's fields of expertise.

The deployment products will be:

1. the air conditioning coil disinfection technologies; and
2. the whole of room air purifier of which the design and testing activity is entering its final pre-production phase.

Initial sales of these products will provide for field pilot sites and hence will not provide material revenue or cost but act as a critical reference site for future sales.

Aspen Medical is a global provider of innovative healthcare solutions in the area of infectious disease prevention and management. By entering these arrangements with Aspen Medical, Purifloh is now delivering on securing leading global distribution partners consistent with its B2B plans.

Previously released third party results confirm Purifloh devices destroy 99.99% of airborne biological and chemical contaminants, including viruses, bacteria, spores, VOC and smoke. (ASX: 17 April 2018 *"Aerosol Test Results"* and 26 June 2018 *"Removal of Cigarette Smoke and Odour"*). These proven outcomes were a key determinant of the interest from Aspen Medical.

"As the technology is effective and chemical and hazard free, it is an ideal solution for frontline staff to manage safely by minimising the potential risk of infection." said Mr Keys.

Purifloh Technical Director, Dr Alex Sava said *"Our technology delivers the assurance of superior air disinfection, not simply purification alone. The powerful free radicals are short-lived, rapidly decomposing into water and oxygen after the disinfection."*

Following successful in situ deployment Purifloh anticipates its products can fit a broad range of settings including hotels and accommodation, workplaces, retail outlets and entertainment venues, lifts, hospitals, aged care and other care facilities, educational facilities, institutional settings, cruise ships and public transport including taxis and rideshare operations.

Purifloh Director Mr Jon Evans said *“Aspen Medical is a leading global provider of innovative and tailored healthcare solutions across a diverse range of sectors, identified as a world leader in infection prevention and control and in COVID-SAFE solutions. Aspen Medical is a leading COVID-19 response service provider to the Australian Government with a number of global engagements.”*

Their initial interest in our products is a validation of our technology that harnesses UV light, free radicals and electrons to eliminate aerosol based biological and chemical contaminants.”

Purifloh’s future technology suite will also include surface disinfection and water sanitisation capabilities as an adjunct to air disinfection.

Approved by the Board of Purifloh Limited

END

For further information:

Jon Evans (Director)
Melbourne, Australia
+ 613 9673 9673

Simon Lill (Director)
Australia
+613 9673 9673